Skip to content
Independent analysis of NHS open data
PharmaInsight

Ritlecitinib 50mg capsules

Secondary Care Medicines Data (SCMD) · indicative cost
Data updated April 2026

NHS hospitals in England used £22,018,194 of indicative cost of Ritlecitinib 50mg capsules in the 12 months to April 2026, about 0.1% of all hospital medicines spend. That is up 205.7% on the previous 12 months.

£22,018,194 +205.7%

Indicative cost · 12 months

695,744units

Quantity (VMP units) · 12 months

0.1%

Share of hospital medicines spend

Figure 1. Ritlecitinib 50mg capsules: NHS hospital indicative cost by month (£ millions)

£0m £1.2m £2.3m Apr 2024 Aug 2024 Dec 2024 Apr 2025 Aug 2025 Dec 2025 Apr 2026 £2.2m Apr 2024: £0.0m May 2024: £0.0m Jun 2024: £0m Jul 2024: £0.1m Aug 2024: £0.1m Sep 2024: £0.4m Oct 2024: £0.4m Nov 2024: £0.9m Dec 2024: £0.8m Jan 2025: £1.0m Feb 2025: £0.8m Mar 2025: £1.5m Apr 2025: £1.2m May 2025: £1.3m Jun 2025: £1.4m Jul 2025: £1.6m Aug 2025: £1.5m Sep 2025: £1.9m Oct 2025: £1.9m Nov 2025: £1.9m Dec 2025: £2.0m Jan 2026: £2.0m Feb 2026: £1.9m Mar 2026: £2.3m Apr 2026: £2.2m

Source: NHSBSA Secondary Care Medicines Data, to April 2026

Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.

NHS trusts using Ritlecitinib 50mg capsules most

By indicative cost over the 12 months to April 2026.

NHS trusts using Ritlecitinib 50mg capsules most, by indicative cost
NHS trustIndicative cost (12 months)
Guy's & St Thomas' Nhs Foundation Trust £1,509,086
Salford Royal Nhs Foundation Trust £1,362,339
Western Sussex Hospitals Nhs Found Trust £703,164
King's College Hpl Nhs Foundation Trust £582,937
Royal Devon & Exeter Nhs Foundation Trst £567,747
Aintree University Hospital Nhs Ft £547,904
Chelsea & Westminster Hospital Nhs Ft £520,276
Barts Health Nhs Trust £507,459
Nottingham University Hospitals Trust £487,047
Derby Teaching Hospitals Nhs Found Trust £454,577

The primary-care picture

Ritlecitinib is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Ritlecitinib medicine page.